Who’s Hired? Sandoz Names Post-Spinoff Chair
As CGPA Announces New Leadership And Formycon Appoints A CFO
Sandoz has announced the appointment of a chairman-designate ahead of its planned separation from parent company Novartis this year. Meanwhile, Canadian industry association the CGPA has also named a new chair and vice-chair, while Formycon has appointed a new CFO.
You may also be interested in...
Sandoz CEO Saynor Talks Spinoff, Leadership And Place Among Peers
In the first part of an exclusive three-part interview, Sandoz CEO Richard Saynor talks to Generics Bulletin about the firm’s upcoming separation from parent company Novartis, as well as outlining its unique position as a pure generics and biosimilars company among an evolving peer group of off-patent industry leaders.
Sandoz Expects ‘Trough Year’ In 2023 As It Counts Cost Of Spinoff
Sandoz is set for a “trough year” in 2023 as the generics and biosimilars unit faces costs linked with its spinoff from parent company Novartis that will erode its core operating income.
Fresenius Kabi And Formycon Ally On Stelara Rival
Fresenius Kabi and Formycon have announced a global licensing deal for the FYB202 ustekinumab proposed biosimilar rival to Stelara. The deal comes as Formycon has revealed plans to raise further funds to funnel into research and development through a fresh share issue.